Clinical Study to Evaluate the Possible Efficacy and Safety of Febuxostat in Patients With Ulcerative Colitis Treated With Mesalamine

Launched by TANTA UNIVERSITY · Jul 24, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medication called febuxostat works and how safe it is for patients with ulcerative colitis who are already being treated with another medication called mesalamine. Ulcerative colitis is a condition that causes inflammation in the digestive tract, leading to symptoms like diarrhea and abdominal pain. The trial is currently not recruiting participants, but it aims to include adults aged 18 and older who have mild to moderate ulcerative colitis confirmed by a medical test called an endoscopy.

To be eligible for this study, participants need to be treated with mesalamine and have a diagnosis of mild or moderate ulcerative colitis. However, people with severe ulcerative colitis, certain serious health conditions, or those taking specific medications will not be able to participate. If you join this trial, you will be monitored to see how febuxostat affects your symptoms and overall health. It's important to know that this trial is still in its early stages, so researchers are gathering information to determine if febuxostat is a good option for treating ulcerative colitis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old.
• • Both male and female will be included.
• • Mild and moderate UC patients diagnosed and confirmed by endoscope.
• • Patient treated with 5-aminosalislic acid (mesalamine).
• Exclusion Criteria:
• • Patients with severe UC.
• • Significant liver and kidney function abnormalities.
• • Diabetic patients.
• • Patients with Colorectal cancer patients.
• • Patients taking rectal or systemic steroids.
• • Patients on immunosuppressants or biological therapies.
• • Addiction to alcohol and / or drugs.
• • Known allergy to the studied medications.
• • History of complete or partial colectomy.
• • Patients with congestive heart failure, other heart disease (Arrhythmia, ischemic heart disease including angina and myocardial infarction).
• • Patients with other inflammatory diseases and active infection.
• • Patients with stressful condition (COPD, morbid obesity).
• • Patients with liver disease.
• • Patients with thrombocytopenia and neutropenia.
• • Pregnant or lactating females.
• • Patients were treated with mercaptopurine.